New drug trial aims to stop dangerous transplant complication
NCT ID NCT07349771
Summary
This study is testing whether adding an experimental drug called axatilimab to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancers receiving a stem cell transplant from a donor. GVHD is a serious complication where the donor's immune cells attack the patient's body. The trial will compare the new combination to standard care alone in 72 patients to see if it improves survival free from severe GVHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.